Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Melanoma-Associated Tumor Antigens (TAAs)
- Target
- TAAs
- Molecular classification
- Protein, Peptide, Differentiation Antigen, Cancer/Testis Antigen, Cell Surface Marker
01
Overview
Melanoma-associated tumor antigens (TAAs) are molecules, often proteins or peptides, expressed by melanoma cells that can be recognized by the immune system. These antigens include differentiation antigens (gp100, Melan-A/MART-1, tyrosinase), cancer/testis antigens (MAGE-A1, MAGE-A4, NY-ESO-1), and cell surface markers (ErbB3, CD44, ICAM-1). They serve as targets for diagnostic assays and immunotherapeutic strategies, including checkpoint inhibitors, adoptive T-cell transfer, cancer vaccines, and monoclonal antibodies. Heterogeneous expression and potential for immune escape remain challenges in targeting these antigens.
- Other names
- Melanoma AntigensTumor-Associated Antigens (Melanoma)Melanoma-Specific Antigens
02
Mechanism of action
Various, including immune checkpoint inhibition, direct cytotoxicity via T-cells, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC)
03
Biological functions
Immune RecognitionT-cell ActivationAntibody BindingTumor Cell ProliferationTumor Cell Survival
04
Disease associations
MelanomaCancerImmune EvasionTumor Progression
05
Safety considerations
Off-tumor toxicity (for differentiation antigens)Cytokine release syndrome (CRS) with adoptive T-cell therapiesImmune-related adverse events (irAEs) with checkpoint inhibitorsTumor heterogeneity and antigen lossDevelopment of resistance
06
Interacting drugs
Anti-PD-1 antibodies (e.g., Nivolumab, Pembrolizumab)
4 more in the full profile.
07
Biomarkers
gp100 expressionMelan-A/MART-1 expressionTyrosinase expressionMAGE-A1 expressionMAGE-A4 expressionNY-ESO-1 expressionErbB3 expressionCD44 expressionICAM-1 expressionCirculating T cells reactive to NY-ESO-1 or Melan-A/MART-1
Beyond the preview
Go deeper on Melanoma-Associated Tumor Antigens (TAAs).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melanoma-Associated Tumor Antigens (TAAs).